New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer care. Hosted by Dr. Neal Shore, Chief Medical Officer...
Leading brand of mosquito repellent for children in the UK Gurkha Protec launches combo package
The British brand that has specialized in mosquito repellent for 40 years is now available! With 40 years dedication and products sold worldwide, Gurkha Protec is launching a two-color combination package BEIJING, March 29, 2022 /PRNewswire/ -- Gurkha Protec was founded in 1981. We have been focusing on researching and developing mosquito repellent products for children for more than 40 years....
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab Seven business development deals, including a US$315M strategic commercial partnership with Jumpcan on eftansomatropin alfa Global pipeline comprised of 10 clinical stage assets, mostly in phase 2 and...
Nippon Express (Middle East) Becomes First Japanese Logistics Company to Acquire GDP Certification in Middle East
TOKYO, March 29, 2022 /PRNewswire/ -- Nippon Express (Middle East) L.L.C. (hereinafter "NX Middle East"), a group company of Nippon Express Holdings, Inc., on February 3, 2022, became the first Japanese logistics company in the Middle East to obtain Good Distribution Practice (GDP) certification for forwarding operations, inclusive of temporary storage, at its Jebel Ali Free Zone Logistics Center...
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant (HSCT). The granting of an ODD for TLX66...
Samsung Biologics holds 11th Annual General Meeting of Shareholders
INCHEON, South Korea, March 28, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), hosted its 11th Annual General Meeting of Shareholders (AGM) today. Five matters were presented and approved unanimously at this year's meeting, which included the approval of financial statement, appointment of directors, appointment of director as audit committee member,...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, March 29, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon &...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong Pharmaceutical expects to strengthen its global business in key markets of ASEAN countries by obtaining marketing authorization in foreign countries with its branch offices SEOUL, South Korea, March 29, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon &...
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
SAN FRANCISCO and SUZHOU, China, March 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced the first patient dosing for its proprietary recombinant bispecific antibody targeting Claudin18.2 and CD3 (R&D code: IBI389) in a...
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
MELBOURNE, Australia and LIÈGE, Belgium, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix's prostate cancer investigational imaging product, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the United Kingdom (U.K.) and the Republic of Ireland. Under...
